Conventional fibrosarcoma

Summary

Conventional fibrosarcoma (MONDO:0002677) is a disease. A subtype of fibrosarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	conventional fibrosarcoma
Mondo ID	MONDO:0002677
DOID	DOID:3517
NCIT	C9429
UMLS	C1333156
MedGen	232393
GARD	0023210
Is cancer (heuristic)	no

Also known as: classic fibrosarcoma · classical fibrosarcoma · conventional fibrosarcoma

Disease family

This is a subtype of fibrosarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › mesenchymal cell neoplasm › fibroblastic neoplasm › fibrosarcoma › conventional fibrosarcoma

Related subtypes (10): bone fibrosarcoma, pediatric fibrosarcoma, kidney fibrosarcoma, breast fibrosarcoma, heart fibrosarcoma, central nervous system fibrosarcoma, small intestinal fibrosarcoma, liver fibrosarcoma, low grade fibromyxoid sarcoma, dermatofibrosarcoma protuberans

Subtypes (2): adult fibrosarcoma, congenital fibrosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.